Attitude counts, federal prosecutor Michael Loucks says in an interview with The RPM Report. When senior management makes a commitment to correct wrongdoing, prosecutors are impressed.
By Michael McCaughan
Big Pharma executives have been spending a lot of time in Boston the past few years, and not just to...
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Bristol Myers Squibb’s Opdivo and Merck's Welireg also could benefit from the delay in Medicare price negotiation process eligibility.
The Center for Biologics Evaluation and Research saw departures far outnumber new hires in the second and third quarters of FY 2025, before more than 100 people left July 14 after the reduction-in-force was finalized.
US FDA's cancer drugs division is feeling the effect of drug reviewer departures, despite efforts to keep them at the agency.
